- Home
- CFSB vs ANL Comparison
CFSB vs ANL Comparison
Compare CFSB & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFSB
- ANL
- Stock Information
- Founded
- CFSB 1889
- ANL 2004
- Country
- CFSB United States
- ANL Cayman Islands
- Employees
- CFSB N/A
- ANL N/A
- Industry
- CFSB Major Banks
- ANL
- Sector
- CFSB Finance
- ANL
- Exchange
- CFSB Nasdaq
- ANL Nasdaq
- Market Cap
- CFSB 51.6M
- ANL 61.8M
- IPO Year
- CFSB N/A
- ANL 2023
- Fundamental
- Price
- CFSB $14.07
- ANL $1.70
- Analyst Decision
- CFSB
- ANL Hold
- Analyst Count
- CFSB 0
- ANL 1
- Target Price
- CFSB N/A
- ANL N/A
- AVG Volume (30 Days)
- CFSB 2.6K
- ANL 10.2K
- Earning Date
- CFSB 10-28-2025
- ANL 09-19-2025
- Dividend Yield
- CFSB N/A
- ANL N/A
- EPS Growth
- CFSB N/A
- ANL N/A
- EPS
- CFSB N/A
- ANL N/A
- Revenue
- CFSB $7,484,000.00
- ANL N/A
- Revenue This Year
- CFSB N/A
- ANL N/A
- Revenue Next Year
- CFSB N/A
- ANL N/A
- P/E Ratio
- CFSB N/A
- ANL N/A
- Revenue Growth
- CFSB N/A
- ANL N/A
- 52 Week Low
- CFSB $6.41
- ANL $1.10
- 52 Week High
- CFSB $14.24
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- CFSB 61.56
- ANL 53.67
- Support Level
- CFSB $13.96
- ANL $1.62
- Resistance Level
- CFSB $14.24
- ANL $1.88
- Average True Range (ATR)
- CFSB 0.05
- ANL 0.10
- MACD
- CFSB 0.01
- ANL 0.00
- Stochastic Oscillator
- CFSB 50.00
- ANL 52.63
About CFSB CFSB Bancorp Inc.
CFSB Bancorp Inc provides banking services. It offers a variety of financial services to individuals and small businesses through its offices in Quincy, Holbrook, and Weymouth. Its primary deposit products are savings, checking, and term certificate accounts, and its primary lending product is residential mortgage loans.The Company's loan portfolio includes residential real estate, commercial real estate, construction, and consumer loan segments. Residential real estate loans include classes for one- to four-family, multi-family, second mortgages and home equity lines of credit.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.